携双抗体纳米微泡对卵巢癌细胞增殖活性的影响  

Effect of nanobubbles carrying double antibodies on the proliferation of ovarian cancer cells

作　　者：吴天 赵越 胡蓉[1] Wu Tian;Zhao Yue;Hu Rong(Xinjiang Key Laboratory of Ultrasound Medicine,Department of Obstetrics and Gynecology Ultrasound,First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,Xinjiang Uygur Autonomous Region,China)

机构地区：[1]新疆医科大学第一附属医院妇产超声诊断科,新疆超声医学重点实验室,新疆维吾尔自治区乌鲁木齐市830054

出　　处：《中国组织工程研究》2024年第3期341-346,共6页Chinese Journal of Tissue Engineering Research

基　　金：国家自然科学基金(81660288),项目负责人:胡蓉;新疆医科大学研究生创新创业项目(CXCY2022008),项目负责人:吴天。

摘　　要：背景:免疫治疗可通过多种途径增强抗肿瘤免疫反应,联合免疫治疗是一个更好的选择。超声靶向微泡破坏技术可将药物、基因、抗体和细胞因子直接输送到免疫细胞的细胞质中,进一步增强免疫应答。然而,通过超声靶向微泡破坏技术将携趋化因子受体4抗体和细胞程序性死亡配体1抗体双靶向纳米微泡应用于卵巢癌的治疗尚未见报道。目的:探讨超声辐照携趋化因子受体4抗体和程序性死亡配体1抗体双靶向纳米微泡对卵巢癌细胞增殖、迁移的影响。方法:对IOSE-80正常卵巢上皮细胞及SKOV3、CAOV3卵巢癌细胞进行培养及扩增,采用双标记荧光免疫法对3种细胞中的趋化因子受体4和细胞程序性死亡配体1蛋白进行共定位,蛋白质印迹法检测3种细胞中趋化因子受体4和程序性死亡配体1蛋白相对表达量,并筛选出实验细胞。制备携不同配体的靶向纳米微泡后,即单纯的纳米微泡、携趋化因子受体4抗体的纳米微泡、携趋化因子受体4和程序性死亡配体1抗体的纳米微泡。取对数生长期的SKOV3卵巢癌细胞,分6组处理:A组加入McCoy’s 5A培养基,B组加入含基质细胞衍生因子1的McCoy’s 5A培养基,C组加入单纯的纳米微泡溶液与含基质细胞衍生因子1的McCoy’s 5A培养基,D组加入携趋化因子受体4抗体的纳米微泡溶液与含基质细胞衍生因子1的McCoy’s 5A培养基,E组加入携趋化因子受体4和程序性死亡配体1抗体的纳米微泡溶液与含基质细胞衍生因子1的McCoy’s 5A培养基,F组加入单纯的纳米微泡溶液,超声辐照120 s,孵育48 h后,采用CCK-8法检测细胞存活率,通过伤口愈合实验检测B-E组细胞的愈合迁移能力。结果与结论:①免疫荧光染色显示,3种细胞均可表达趋化因子受体4和程序性死亡配体1蛋白;蛋白质印迹法检测显示,SKOV3、CAOV3卵巢癌细胞中的趋化因子受体4和程序性死亡配体1蛋白表达量均高于IOSEBACKGROUND:Immunotherapy enhances the anti-cancer immune response in many ways,so combined immunotherapy is a better choice.Ultrasoundtargeted microbubble destruction technique delivers drugs,genes,antibodies and cytokines directly to the cytoplasm of immune cells and enhances the immune response.However,the application of ultrasound-targeted microbubble destruction technique in the treatment of ovarian cancer with both CXC chemokine receptor 4 antibody and programmed death-ligand 1 antibody has not been reported.OBJECTIVE:To investigate the effect of ultrasound irradiation on the proliferation and migration of ovarian cancer cells with CXC chemokine receptor 4 antibody and programmed death-ligand 1 antibody double targeted nanobubbles.METHODS:IOSE-80 normal ovarian epithelial cells,SKOV3 and CAOV3 ovarian cancer cells were cultured and expanded.Double labeling fluorescence immunoassay was used to co-locate CXC chemokine receptor 4 and programmed death-ligand 1 protein.Western blot assay was used to detect the relative expression of CXC chemokine receptor 4 and programmed death-ligand 1 protein in three kinds of cells and screen out the experimental cells,i.e.,pure nanobubbles,nanobubbles carrying CXC chemokine receptor 4 antibody,nanobubbles carrying CXC chemokine receptor 4 and programmed death-ligand 1 antibody.SKOV3 ovarian cancer cells in the logarithmic growth phase were taken and divided into six groups for treatment.Group A was added with McCoy's 5A medium.Group B was added with McCoy's 5A medium containing stromal cell-derived factor-1.Group C was added with pure nanobubble solution and McCoy's 5A medium containing stromal cell-derived factor-1.Group D was added with nanobubble solution containing CXC chemokine receptor 4 antibody and McCoy's 5A medium containing stromal cell-derived factor-1.Group E was added with nanobubble solution containing CXC chemokine receptor 4 and programmed death-ligand 1 antibody and McCoy's 5A medium containing stromal cell-derived factor-1.Pure nanobubble solution was added

关 键 词：卵巢肿瘤 增殖 靶向纳米微泡 超声靶向微泡破坏 趋化因子受体4(CXCR4) 程序性死亡配体1(PD-L1) 

分 类 号：R459.9[医药卫生—治疗学] R318.08[医药卫生—临床医学] R73-36